NEW YORK, November 23, 2016 /PRNewswire/ --
www.Financialbuzz.com - California was one of the four states where
cannabis for recreational use has voted in favor, and is now legal.
California is the largest market
for the legal cannabis industry to tackle, as 12 percent of
Americans reside in the state. The impact the western state will
have on the industry is still unclear, and analysts are presenting
different projections, yet all suggest that growth will be there.
Vivien Azer, a cannabis analyst from
Cowen Group Inc. indicated in a report that sales of recreational
and medical marijuana will reach $50
billion by 2026. Canadian Zeolite Corp. (OTC: CNZCF)
(CNZ.V), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Cara
Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ:
INSY), GW Pharmaceuticals (NASDAQ: GWPH).
Canada is not far behind
the United States when it comes to
legalization of cannabis. Canada
is moving to potentially legalize cannabis in 2017, as the current
Liberal Party government will introduce reforms next spring to
legalize cannabis for recreational use not just medical.
Canadian Zeolite Corp. (OTCQB: CNZCF) (TSX-V: CNZ) is an
environmentally friendly Green Tech business, with a focus on
exploration, development and production of the industrial mineral
zeolite. The mineral is a naturally occurring mineral found in
volcanic ash, and is beneficial to for several industries thanks to
its crystalline structure perforated by microscopic pores that act
as natural filters. In the agricultural industry, the properties of
zeolite are beneficial for use in odor and moisture control in
municipal composting, animal feed supplements, zeoponics for
greenhouse growing mediums and high-value outdoor zeolitic
fertilizers.
This morning Canadian Zeolite Corp. announced that, "it has
reached a Supplier Agreement with Natural Ventures, a Puerto Rico based licensed grower and
manufacturer of medical marijuana. Canadian Zeolite will now be
working with Natural Ventures to enhance their growing production
per square foot with zeolitic fertilizers and substrates.
Natural Ventures is located near San
Juan, Puerto Rico and has an indoor growing facility of
100,000 square feet. Currently there are over 60,000 registered
medical marijuana patients in Puerto
Rico and that number is expected to increase significantly
in 2017. Natural Ventures CEO, Edgar
Montero stated, "we are very excited to be implementing a
natural Zeolitic fertilizer for our 2017 crop. With an
expected increase in crop yield, we anticipate being able to fully
service the increase in demand for our product in Puerto Rico and the other parts of the
Caribbean market as they
open."
Canadian Zeolite CEO Ray Paquette
stated, "we are extremely pleased to be supplying Natural Ventures
of Puerto Rico. Plant nutritional
needs vary between different species and zeolites are considered as
good substrates for developing slow release fertilizers. Canadian
Zeolite's natural zeolite is being developed as a value added and
highly efficient soil-less substrate for growing a wide variety of
plants including medical marijuana."
The first synthetic cannabidiol formulated as a
permeation-enhanced gel developed for refractory Epilepsy,
Osteoarthritis and Fragile X Syndrome, was created by Zynerba
Pharmaceuticals Inc. (NASDAQ: ZYNE). The ZYN002 is a synthetic
cannabidiol formulated as a permeation-enhanced gel for transdermal
delivery. These transdermal therapeutics travel through the skin
directly into the systemic circulation, dodging first-pass liver
metabolism and thus enabling lower dosage levels of active
pharmaceutical ingredients and rapid and reliable absorption with
increased bioavailability. During its clinical trials, ZYN002 has
proved to show no signs of somnolence or fatigue and has a very low
incidence of gastrointestinal events.
Cara Therapeutics Inc. (NASDAQ: CARA) focuses on
developing and commercializing new chemical entities intended to
ease pain and pruritus by targeting kappa opioid receptors. The
company uses a proprietary class of product candidates that target
the body's nervous system and have confirmed efficacy in patients
with moderate-to-severe pain without encouraging many of the
unwanted side effects typically associated with currently available
pain therapeutics. Cara's most advanced pipeline product,
intravenous, or I.V., CR845, has demonstrated significant pain
relief and a favorable safety and tolerability profile in three
Phase 2 clinical trials in patients with acute postoperative pain.
We are also developing I.V. CR845 in uremic pruritus, and as well
as an oral version of CR845, or Oral CR845, for acute and chronic
pain.
Researchers at Insys Therapeutics Inc. (NASDAQ: INSY) is
currently in study, but not open yet for participant recruitment of
a cannabidiol oral solution to act as an adjunctive therapy for
treatment of subjects with Lennox-Gastaut Syndrome. According to
the Phase 3 trial, they will enroll participants diagnosed with
Lennox-Gastaut Syndrome who are still experiencing at least 4 motor
seizures involving the trunk or extremities per week, despite
ongoing treatment with up to 3 antiepileptic drugs and who meet
inclusion/exclusion criteria. Following a 28-day baseline period,
subjects will begin an 84-day treatment period. Participants will
be assigned to receive twice daily doses of placebo or cannabidiol
oral solution at the highest dose determined to be safe in a
previous trial.
GW Pharmaceuticals (NASDAQ: GWPH) main focus is on
disorders of the central nervous system with epilepsy. GW
Pharmaceuticals has a deep pipeline of cannabinoid product
candidates which include compounds in development for epilepsy,
glioma and schizophrenia. The company owns Epidiolex®, a liquid
formulation of pure plant-derived cannabidiol which is in
development for the treatment of a number of rare childhood-onset
epilepsy disorders. The company also commercialized its very first
plant-derived cannabinoid prescription drug, Sativex®, which is
approved for the treatment of spasticity.
For "The Latest Buzz in Financial News", SIGN UP & Visit:
http://www.FinancialBuzz.com
Subscribe Now! Watch us report from NYSE
https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates:
https://twitter.com/financialbuzz
Follow and talk to us on Instagram:
https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds:
https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web
portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth
broadcasts on Stock News, Market Analysis and Company Interviews. A
pioneer in the financially driven digital space, video production
and integration of social media, FinancialBuzz.com creates 100%
unique original content. FinancialBuzz.com also provides financial
news PR branding, marketing and advertising for third parties for
disseminating news and original content through our unique media
platform that includes Newswire Delivery, Digital Advertising,
Social Media Relations, Video Production, Broadcasting, and
Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or
advisor, investment advisor or broker-dealer and do not undertake
any activities that would require such registration. The
information provided on http://www.FinancialBuzz.com (the "Site")
is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content),
FinancialBuzz.com, a financial news media and pr marketing firm
enters into service agreements with the companies which are the
subject to the articles posted on the Site for advertising such
companies. Financialbuzz.com has been compensated four thousand dollars for financial news
dissemination and pr services by a non-affiliated third party for
canadian zeolite corp. We are not an independent news media
provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete.
FinancialBuzz.com receives fees for producing and presenting high
quality and sophisticated content on this site along with other
financial news pr media services. Our fees may be either a flat
cash sum or negotiated number of securities of the companies
featured on this site, or a combination thereof. The securities are
commonly paid in segments, of which a portion is received upon
engagement and the balance is paid on or near the conclusion of the
engagement. FinancialBuzz.com does not undertake to update any of
the information on the Site or continue to post information about
any companies the information contained herein is not intended to
be used as the basis for investment decisions and should not be
considered as investment advice or a recommendation. The
information contained herein is not an offer or solicitation to
buy, hold or sell any security. FinancialBuzz.com, members and
affiliates are not responsible for any gains or losses that result
from the opinions expressed on the Site, company profiles,
quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility
for any and all of their investment decisions based on their own
independent research and evaluation of their own investment goals,
risk tolerance, and financial condition. FinancialBuzz.com. By
accessing this website and any pages thereof, you agree to be bound
by the Terms of Use and Privacy Policy, as may be amended from time
to time. None of the content issued by FinancialBuzz.com
constitutes a recommendation for any investor to purchase, hold or
sell any particular security, pursue a particular investment
strategy or that any security is suitable for any investor. This
publication is provided by FinancialBuzz.com. Each investor is
solely responsible for determining whether a particular security or
investment strategy is suitable based on their objectives, other
securities holdings, financial situation needs, and tax status. You
agree to consult with your investment advisor, tax and legal
consultant before making any investment decisions. We make no
representations as to the completeness, accuracy or timeless of the
material provided. All materials are subject to change without
notice. Information is obtained from sources believed to be
reliable, but its accuracy and completeness are not guaranteed. For
our full disclaimer, disclosure and Terms of Use. Please visit:
http://www.financialbuzz.com
For further information:
Media Contact: Danny A, info@financialbuzz.com,
+1-877-601-1879
SOURCE FinancialBuzz.com